The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review
Open accessAbstract
The role of N-acetylcysteine (NAC) in the treatment of chronic bronchitis is unclear. Since a number of studies have been published on this topic, a systematic review of published studies seems justified. A systematic search (Medline, Embase, Cochrane Library, bibliographies, no language restriction) for published randomized trials comparing oral NAC with placebo in patients with chronic bronchitis was performed. Dichotomous data on prevention of exacerbation, improvement of symptoms and adverse effects were extracted from original reports. The relative benefit and number-needed-to-treat were calculated for both individual trials and combined data. Thirty-nine trials were retrieved; eleven (2,011 analysed patients), published 1976-1994, were regarded as relevant and valid according to preset criteria. In nine studies, 351 of 723 (48.5%) patients receiving NAC had no exacerbation compared with 229 of 733 (31.2%) patients receiving placebo (relative benefit 1.56 (95% confidence interval (CI) 1.37-1.77), number-needed-to-treat 5.8 (95% CI 4.5-8.1). There was no evidence of any effect of study period (12-24 weeks) or cumulative dose of NAC on efficacy. In five trials, 286 of 466 (61.4%) patients receiving NAC reported improvement of their symptoms compared with 160 of 462 (34.6%) patients receiving placebo (relative benefit 1.78 (95% CI 1.54-2.05), number-needed-to-treat 3.7 (95% CI 3.0-4.9)). With NAC, 68 of 666 (10.2%) patients reported gastrointestinal adverse effects compared with 73 of 671 (10.9%) taking placebo. With NAC, 79 of 1,207 (6.5%) patients withdrew from the study due to adverse effects, compared with 87 of 1,234 (7.1%) receiving placebo. In conclusion, with treatment periods of approximately 12-24 weeks, oral N-acetylcysteine reduces the risk of exacerbations and improves symptoms in patients with chronic bronchitis compared with placebo, without increasing the risk of adverse effects. Whether this benefit is sufficient to justify the routine and long-term use of N-acetylcysteine in all patients with chronic bronchitis should be addressed in further studies and cost-effectiveness analyses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease
Celli, B. R., Snider, G. L., Heffner, J. E., Tiep, B. L., Ziment, I., Make, B. J., Braman, S. S., Olsen, G. N., & D, Y. Y. P. M. (1995) · Cited by 3,506
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205 · cited 1×
“A fixed effect model [ 15 ] was used when data were combined.”
MethodChronic Obstructive Pulmonary Disease
(2018) · Questions for the Final FFICM Structured Oral Examination · doi:10.1017/9781108233712.025 · Cited by 2,689
The natural history of chronic airflow obstruction.
Fletcher, C., & Peto, R. (1977) · BMJ · doi:10.1136/bmj.1.6077.1645 · Cited by 2,370
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
An Assessment of Clinically Useful Measures of the Consequences of Treatment
Laupacis, A., Sackett, D. L., & Roberts, R. S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182605 · Cited by 1,681 · cited 1×
“A statistically significant difference between NAC and control was assumed when the 95% CI of the relative benefit or risk did not include 1. As an estimate of the clinical relevance of a treatment effect, the number-needed-to-treat [ 16 ] was calculated for both individual trials and combined data.”
MethodSiafakas, N., Vermeire, P., Pride, N., Paoletti, P., Gibson, J., Howard, P., Yernault, J., Decramer, M., Higenbottam, T., Postma, D., et al. (1995) · European Respiratory Journal · doi:10.1183/09031936.95.08081398 · Cited by 1,592
Connors, A. F., Dawson, N. V., Thomas, C., Harrell, F. E., Desbiens, N., Fulkerson, W. J., Kussin, P., Bellamy, P., Goldman, L., & Knaus, W. A. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.154.4.8887592 · Cited by 1,393
Cited by
Oxidative stress and redox regulation of lung inflammation in COPD
Rahman, I., & Adcock, I. M. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00053805 · Cited by 944
Guidelines for the management of adult lower respiratory tract infections
Woodhead, M., Blasi, F., Ewig, S., Huchon, G., Leven, M., Ortqvist, A., Schaberg, T., Torres, A., van der Heijden, G., & Verheij, T. J. M. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00055705 · Cited by 895
N-Acetylcysteine—a safe antidote for cysteine/glutathione deficiency
Atkuri, K. R., Mantovani, J. J., Herzenberg, L. A., & Herzenberg, L. A. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.04.005 · Cited by 721
Rushworth, G. F., & Megson, I. L. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.006 · Cited by 719
Decramer, M., Rutten-van Mölken, M., Dekhuijzen, P. R., Troosters, T., van Herwaarden, C., Pellegrino, R., van Schayck, C. O., Olivieri, D., Del Donno, M., De Backer, W., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66456-2 · Cited by 684
COPD exacerbations: definitions and classifications
Burge, S., & Wedzicha, J. A. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00078002 · Cited by 664
Oxidative stress and lung inflammation in airways disease
MacNee, W. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01320-6 · Cited by 556
Guidelines for the management of adult lower respiratory tract infections - Summary
Woodhead, M., Blasi, F., Ewig, S., Garau, J., Huchon, G., Ieven, M., Ortqvist, A., Schaberg, T., Torres, A., van der Heijden, G., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03602.x · Cited by 468
Antioxidant Therapy: Current Status and Future Prospects
Firuzi, O., Miri, R., Tavakkoli, M., & Saso, L. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711803414368 · Cited by 468
Impact of exacerbations on COPD
Anzueto, A. (2010) · European Respiratory Review · doi:10.1183/09059180.00002610 · Cited by 353
De Flora, S., Izzotti, A., D'Agostini, F., & Balansky, R. M. (2001) · Carcinogenesis · doi:10.1093/carcin/22.7.999 · Cited by 351
Environmental toxicity, redox signaling and lung inflammation: The role of glutathione
Biswas, S. K., & Rahman, I. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.07.001 · Cited by 344
Sadowska, A. M., Manuel-y-Keenoy, B., & De Backer, W. A. (2007) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2005.12.007 · Cited by 325
Dekhuijzen, P. N. R. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00016804 · Cited by 317
Oxidative stress and free radicals in COPD – implications and relevance for treatment
Domej, W., Oetll, K., & Renner, W. (2014) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s51226 · Cited by 307
A Review on Various Uses of N-Acetyl Cysteine.
Mokhtari, V., Afsharian, P., Shahhoseini, M., Kalantar, S. M., & Moini, A. (2017) · PubMed · doi:10.22074/cellj.2016.4872 · Cited by 304
Molecular Strategies for Targeting Antioxidants to Mitochondria: Therapeutic Implications
Apostolova, N., & Victor, V. M. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2014.5952 · Cited by 299
Pharmacological antioxidant strategies as therapeutic interventions for COPD
Rahman, I. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.004 · Cited by 117
Antioxidants and Chronic Obstructive Pulmonary Disease
Vézina, F.-A., & Cantin, A. M. (2018) · Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation · doi:10.15326/jcopdf.5.4.2018.0133 · Cited by 34
Onadeko, B. O., Khadadah, M., Abdella, N., Mukhtar, M., Mourou, M., Qurtom, M., Samad, M., & Al-Shayeb, A. (2005) · Medical Principles and Practice · doi:10.1159/000081921 · Cited by 16
Metadata
- Authors
- Stey, C., Steurer, J., Bachmann, S., Medici, T. C., & Tramèr, M. R.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2000-08
- Volume
- 16
- Issue
- 2
- Pages
- 253
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2135682290
- Cited by
- 284
- References
- 28
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.